Investigation to Determine Safety of Taperloc Stems With BioGuard Coating When Used in Cementless Total Hip Arthroplasty
← catalyst calendarSponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
50actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2013 | actual | When the study began enrolling |
| Primary completion | Nov 2015 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2014-10-13 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-08-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Osteoarthritis of Hip
Interventions
- Device: Bioguard Group — also filed as Bioguard device
- Device: Control Group — also filed as Exceed Taperlock
Primary outcome
what the primary-completion date above is the date OFChange in normalised peri-implant BMD as measured by DXA
measured 6 months post operative
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed